106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia
Objective: Determine impact of degludec / liraglutide (ideglira) on HBA1c, fasting glucose, total daily insulin dose (TDID), hypoglycemia in adults with type II Diabetes Mellitus (T2DM), during covid-19 and follow-up by teleconsultation Methods: Secondary analysis of an anonymized database of sixty...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2021-06, Vol.70 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 70 |
| creator | PARRA SERRANO, GUSTAVO A. TORRESLANGHAMMER, MARIA PAULA SERRANOGOMEZ, SERGIO PINTOARIAS, ANDREA J. |
| description | Objective: Determine impact of degludec / liraglutide (ideglira) on HBA1c, fasting glucose, total daily insulin dose (TDID), hypoglycemia in adults with type II Diabetes Mellitus (T2DM), during covid-19 and follow-up by teleconsultation
Methods: Secondary analysis of an anonymized database of sixty one patients with T2DM, evaluated hba1c, fasting glucose, TDID, and hypoglycemic episodes, Before, 3 and 6 months after IDEGLIRA. Weight could not me measured due to teleconsultation limitation. Performed univariated analysis of cuantitative viariables, bivariated analysis of clinical variables pre and post ideglira treatment. patients received tele-education by a diabetes educator for insulin titration
Results: 59% women, previos IDEGLIRA: 45.9% used 1 oral antidiabetic 29.5% used 2 and 55.7% used oral antidiabetics plus insulin. 54.1% used basal insulin regimen, the mean TDID was 38 units previous ideglira use, and 26 U after use (p= 0.0001). The mean for HBA1c levels was 8.44% (SD:1.4) prior to the use of ideglira, 7.78% (SD: 0.9) at 3rd month and 7.4% (SD:0.91) at 6th month. Significant differences were found when comparing zero months to three months (p= 0.01), and zero to six months (p= 0.0001), and comparing 3 and 6 months (p=0.003). Goal of hba1c |
| doi_str_mv | 10.2337/db21-106-LB |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2562266896</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2562266896</sourcerecordid><originalsourceid>FETCH-LOGICAL-c646-92107602116efead624a00a97efc4d89defb579117267e028d163e230ce3bf423</originalsourceid><addsrcrecordid>eNotkc2OEzEQhC0EEmHhxAu0xBEM_sna8d42yS5EGrQIAuI26vG0g1cTO3hmhOZpeFUmCupDqaWvqg7F2Gsp3iut7Ye2UZJLYXi1fsIW0mnHtbI_n7KFEFJxaZ19zl70_aMQwsy3YH8v9A18Jex4FQPBXQjRo58AUwvfMNAwQQ6w29KhigUhJthPJwIF24gNDdHDFxwipaGHdiwxHWDz8GO35dLdwC0Y_jmn4Rfc567Lf_j3EzQT7Kkjn1M_dsNszekcuh49FjxiOuA72OQuH5uIL9mzgF1Pr_7rFdvf3-03n3j18HG3ua24N0vDnZLCGqGkNBQIW6OWKAQ6S8Ev25VrKTTX1klplbEk1KqVRpPSwpNuwlLpK_bmEnsq-fdI_VA_5rGkubFW10YpY1bOzNTbC-VL7vtCoT6VeMQy1VLU5wHq8wDzY-pqrf8B4Kx17g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562266896</pqid></control><display><type>article</type><title>106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>PARRA SERRANO, GUSTAVO A. ; TORRESLANGHAMMER, MARIA PAULA ; SERRANOGOMEZ, SERGIO ; PINTOARIAS, ANDREA J.</creator><creatorcontrib>PARRA SERRANO, GUSTAVO A. ; TORRESLANGHAMMER, MARIA PAULA ; SERRANOGOMEZ, SERGIO ; PINTOARIAS, ANDREA J.</creatorcontrib><description>Objective: Determine impact of degludec / liraglutide (ideglira) on HBA1c, fasting glucose, total daily insulin dose (TDID), hypoglycemia in adults with type II Diabetes Mellitus (T2DM), during covid-19 and follow-up by teleconsultation
Methods: Secondary analysis of an anonymized database of sixty one patients with T2DM, evaluated hba1c, fasting glucose, TDID, and hypoglycemic episodes, Before, 3 and 6 months after IDEGLIRA. Weight could not me measured due to teleconsultation limitation. Performed univariated analysis of cuantitative viariables, bivariated analysis of clinical variables pre and post ideglira treatment. patients received tele-education by a diabetes educator for insulin titration
Results: 59% women, previos IDEGLIRA: 45.9% used 1 oral antidiabetic 29.5% used 2 and 55.7% used oral antidiabetics plus insulin. 54.1% used basal insulin regimen, the mean TDID was 38 units previous ideglira use, and 26 U after use (p= 0.0001). The mean for HBA1c levels was 8.44% (SD:1.4) prior to the use of ideglira, 7.78% (SD: 0.9) at 3rd month and 7.4% (SD:0.91) at 6th month. Significant differences were found when comparing zero months to three months (p= 0.01), and zero to six months (p= 0.0001), and comparing 3 and 6 months (p=0.003). Goal of hba1c <7% was 10% before ideglira, 19% at 3rd month and 43% at 6th month, There was statistical diference between 0 to 3 and 0 to 6th month (p= 0.01). Mean fasting glucose level was 149.1 mg/dL, 125.4 mg/dL and 108.9 mg/dL for 0, 3 and 6 months respectively. Differences were found between 0 and 3 months (p=0,04), and 0 and 6 months (p= 0.01). None of these patients presented any episode of severe hypoglycemia during follow up.
Conclusion: in this real life COVID-19 teleconsultation follow up for 3 and 6 months, The use of ideglira showed statistically significant changes on HBA1c, fasting glucose levels and TDID without causing severe hypoglycemia.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db21-106-LB</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Coronaviruses ; COVID-19 ; Diabetes ; Diabetes mellitus ; Dosage ; Fasting ; Glucose ; Hypoglycemia ; Insulin ; Patients ; Statistical analysis ; Titration</subject><ispartof>Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>PARRA SERRANO, GUSTAVO A.</creatorcontrib><creatorcontrib>TORRESLANGHAMMER, MARIA PAULA</creatorcontrib><creatorcontrib>SERRANOGOMEZ, SERGIO</creatorcontrib><creatorcontrib>PINTOARIAS, ANDREA J.</creatorcontrib><title>106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia</title><title>Diabetes (New York, N.Y.)</title><description>Objective: Determine impact of degludec / liraglutide (ideglira) on HBA1c, fasting glucose, total daily insulin dose (TDID), hypoglycemia in adults with type II Diabetes Mellitus (T2DM), during covid-19 and follow-up by teleconsultation
Methods: Secondary analysis of an anonymized database of sixty one patients with T2DM, evaluated hba1c, fasting glucose, TDID, and hypoglycemic episodes, Before, 3 and 6 months after IDEGLIRA. Weight could not me measured due to teleconsultation limitation. Performed univariated analysis of cuantitative viariables, bivariated analysis of clinical variables pre and post ideglira treatment. patients received tele-education by a diabetes educator for insulin titration
Results: 59% women, previos IDEGLIRA: 45.9% used 1 oral antidiabetic 29.5% used 2 and 55.7% used oral antidiabetics plus insulin. 54.1% used basal insulin regimen, the mean TDID was 38 units previous ideglira use, and 26 U after use (p= 0.0001). The mean for HBA1c levels was 8.44% (SD:1.4) prior to the use of ideglira, 7.78% (SD: 0.9) at 3rd month and 7.4% (SD:0.91) at 6th month. Significant differences were found when comparing zero months to three months (p= 0.01), and zero to six months (p= 0.0001), and comparing 3 and 6 months (p=0.003). Goal of hba1c <7% was 10% before ideglira, 19% at 3rd month and 43% at 6th month, There was statistical diference between 0 to 3 and 0 to 6th month (p= 0.01). Mean fasting glucose level was 149.1 mg/dL, 125.4 mg/dL and 108.9 mg/dL for 0, 3 and 6 months respectively. Differences were found between 0 and 3 months (p=0,04), and 0 and 6 months (p= 0.01). None of these patients presented any episode of severe hypoglycemia during follow up.
Conclusion: in this real life COVID-19 teleconsultation follow up for 3 and 6 months, The use of ideglira showed statistically significant changes on HBA1c, fasting glucose levels and TDID without causing severe hypoglycemia.</description><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Dosage</subject><subject>Fasting</subject><subject>Glucose</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Patients</subject><subject>Statistical analysis</subject><subject>Titration</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNotkc2OEzEQhC0EEmHhxAu0xBEM_sna8d42yS5EGrQIAuI26vG0g1cTO3hmhOZpeFUmCupDqaWvqg7F2Gsp3iut7Ye2UZJLYXi1fsIW0mnHtbI_n7KFEFJxaZ19zl70_aMQwsy3YH8v9A18Jex4FQPBXQjRo58AUwvfMNAwQQ6w29KhigUhJthPJwIF24gNDdHDFxwipaGHdiwxHWDz8GO35dLdwC0Y_jmn4Rfc567Lf_j3EzQT7Kkjn1M_dsNszekcuh49FjxiOuA72OQuH5uIL9mzgF1Pr_7rFdvf3-03n3j18HG3ua24N0vDnZLCGqGkNBQIW6OWKAQ6S8Ev25VrKTTX1klplbEk1KqVRpPSwpNuwlLpK_bmEnsq-fdI_VA_5rGkubFW10YpY1bOzNTbC-VL7vtCoT6VeMQy1VLU5wHq8wDzY-pqrf8B4Kx17g</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>PARRA SERRANO, GUSTAVO A.</creator><creator>TORRESLANGHAMMER, MARIA PAULA</creator><creator>SERRANOGOMEZ, SERGIO</creator><creator>PINTOARIAS, ANDREA J.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20210601</creationdate><title>106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia</title><author>PARRA SERRANO, GUSTAVO A. ; TORRESLANGHAMMER, MARIA PAULA ; SERRANOGOMEZ, SERGIO ; PINTOARIAS, ANDREA J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c646-92107602116efead624a00a97efc4d89defb579117267e028d163e230ce3bf423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Dosage</topic><topic>Fasting</topic><topic>Glucose</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Patients</topic><topic>Statistical analysis</topic><topic>Titration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PARRA SERRANO, GUSTAVO A.</creatorcontrib><creatorcontrib>TORRESLANGHAMMER, MARIA PAULA</creatorcontrib><creatorcontrib>SERRANOGOMEZ, SERGIO</creatorcontrib><creatorcontrib>PINTOARIAS, ANDREA J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PARRA SERRANO, GUSTAVO A.</au><au>TORRESLANGHAMMER, MARIA PAULA</au><au>SERRANOGOMEZ, SERGIO</au><au>PINTOARIAS, ANDREA J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2021-06-01</date><risdate>2021</risdate><volume>70</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Objective: Determine impact of degludec / liraglutide (ideglira) on HBA1c, fasting glucose, total daily insulin dose (TDID), hypoglycemia in adults with type II Diabetes Mellitus (T2DM), during covid-19 and follow-up by teleconsultation
Methods: Secondary analysis of an anonymized database of sixty one patients with T2DM, evaluated hba1c, fasting glucose, TDID, and hypoglycemic episodes, Before, 3 and 6 months after IDEGLIRA. Weight could not me measured due to teleconsultation limitation. Performed univariated analysis of cuantitative viariables, bivariated analysis of clinical variables pre and post ideglira treatment. patients received tele-education by a diabetes educator for insulin titration
Results: 59% women, previos IDEGLIRA: 45.9% used 1 oral antidiabetic 29.5% used 2 and 55.7% used oral antidiabetics plus insulin. 54.1% used basal insulin regimen, the mean TDID was 38 units previous ideglira use, and 26 U after use (p= 0.0001). The mean for HBA1c levels was 8.44% (SD:1.4) prior to the use of ideglira, 7.78% (SD: 0.9) at 3rd month and 7.4% (SD:0.91) at 6th month. Significant differences were found when comparing zero months to three months (p= 0.01), and zero to six months (p= 0.0001), and comparing 3 and 6 months (p=0.003). Goal of hba1c <7% was 10% before ideglira, 19% at 3rd month and 43% at 6th month, There was statistical diference between 0 to 3 and 0 to 6th month (p= 0.01). Mean fasting glucose level was 149.1 mg/dL, 125.4 mg/dL and 108.9 mg/dL for 0, 3 and 6 months respectively. Differences were found between 0 and 3 months (p=0,04), and 0 and 6 months (p= 0.01). None of these patients presented any episode of severe hypoglycemia during follow up.
Conclusion: in this real life COVID-19 teleconsultation follow up for 3 and 6 months, The use of ideglira showed statistically significant changes on HBA1c, fasting glucose levels and TDID without causing severe hypoglycemia.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db21-106-LB</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2562266896 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Coronaviruses COVID-19 Diabetes Diabetes mellitus Dosage Fasting Glucose Hypoglycemia Insulin Patients Statistical analysis Titration |
| title | 106-LB: Real-Life Efficacy and Safety of IDegLira in Type 2 Diabetic Patients during COVID-19: A 6-Month Follow-Up by Teleconsultation in Bucaramanga, Colombia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A53%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=106-LB:%20Real-Life%20Efficacy%20and%20Safety%20of%20IDegLira%20in%20Type%202%20Diabetic%20Patients%20during%20COVID-19:%20A%206-Month%20Follow-Up%20by%20Teleconsultation%20in%20Bucaramanga,%20Colombia&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=PARRA%20SERRANO,%20GUSTAVO%20A.&rft.date=2021-06-01&rft.volume=70&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db21-106-LB&rft_dat=%3Cproquest_cross%3E2562266896%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2562266896&rft_id=info:pmid/&rfr_iscdi=true |